Revolution Medicines (RVMDW) Other Accumulated Expenses (2019 - 2026)

Revolution Medicines' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 400.92% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 400.92% YoY), while the FY2025 annual figure was $7.9 million, up 1247.86% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.3 million, down from $7.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.2 million in Q3 2025, with the low at $280000.0 in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $647000.0 (2022), against an average of $1.8 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 85.04% in 2024, then jumped 1247.86% in 2025.
• Revolution Medicines' Other Accumulated Expenses stood at $505000.0 in 2022, then jumped by 671.49% to $3.9 million in 2023, then tumbled by 85.04% to $583000.0 in 2024, then surged by 1247.86% to $7.9 million in 2025, then sank by 58.5% to $3.3 million in 2026.
• Business Quant data shows RVMDW's Other Accumulated Expenses at $3.3 million in Q1 2026, $7.9 million in Q4 2025, and $8.2 million in Q3 2025.